PND65 A Comparison of Demographic and Clinical Variables of Down Syndrome Patients in Utah and the United States  by Jiao, T. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A629
ment was associated with 38% fewer unplanned admissions (981 vs. 604, X1
2 = 
89.2, p< 0.001) and 58% fewer unplanned bed nights (8,817 vs. 3,681, X12 = 2109.8, 
p< 0.001) in the year following treatment initiation compared with the year before. 
A 14% reduction in all outpatient appointments was also observed, due principally 
to a 25% reduction in neurological outpatient appointments (from 7,826 to 5,901, 
X1
2 = 269.7, p< 0.001). Evidence from this study indicates that duration of treat-
ment is a significant factor in this response; patients receiving between 12 and 
14 doses (n= 1,122) experienced 70% reduction in unplanned admissions and 90% 
reduction in unplanned bed nights. ConClusions: Our data support the notion 
that natalizumab treatment significantly reduces unplanned hospital treatment 
and outpatient attendance.
PND63
PrescribiNg PatterNs of ParkiNsoN’s Disease
Tomita N., Kanatani Y.
National Institute of Public Health, Wako, Japan
objeCtives: Parkinson’s disease has the second largest number of patients among 
56 designated diseases/syndrome of the Specified Disease Treatment Research 
Programme for rare and intractable disease programme. The purpose of this study 
were to investigate prescribing patterns of Parkinson’s disease and its pharmaceuti-
cal expenditures. Methods: We analysed the Social Health Insurance (SHI) claims 
data processed from February to April 2011 provided by the Planning, Review and 
Research Institute for Social Insurance and Medical Program. Results: During the 
three months, 52,851 patients in Social Health Insurance programme received medi-
cal treatments that cost 9,391,451,520 JPY. Average costs for inpatient care without 
meal expense and for outpatient care were 263,782 JPY and 33,209 JPY respectively. 
Except the cases that fell into Diagnosis Procedure Combination (DPC), 37% of the 
total cost, 3,515,091,420 JPY was for pharmaceutical expenditure including dispens-
ing fee. Only 7,437,873 (23.5%) of 31,699,153 dispensed drugs were generics on a 
volume basis. If all the pharmaceutical that have generics had been substituted, 
estimated 899,586,280 JPY would have been saved in the study period by simple 
arithmetic. Generic usage is fewer in the elderly than in the younger generation in 
all therapeutic categories. ConClusions: Percentage of pharmaceutical expend-
iture in total health expenditure for Parkinson’s disease is high. Our study find 
that generic substitution rate is low in general and even lower in the elderly. This 
might be partly related to the medical expense subsidy under the Specified Disease 
Treatment Research Programme, which exempts eligible patients from co-payment 
according to their income. There seems to be a room for prescribing pattern change 
for cost optimization and further study is expected.
PND64
costs of formal aND iNformal Home care aND Quality of life of 
PatieNts witH multiPle sclerosis iN sweDeN
Svensson M.1, Fajutrao L.2
1The Swedish Institute for Health Economics, Lund, Sweden, 2Merck Serono, Solna, Sweden
objeCtives: To describe and to estimate costs of formal and informal home care 
and quality of life related to multiple sclerosis. Methods: A random sample of 
1500 members of the Swedish organization for patients with neurological diseases 
(NHR), specifically MS, were mailed a questionnaire between February-March 2012. 
Collected data included number of hours per month of home care received, type 
of help, productivity losses, quality of life (EQ-5D) and disease characteristics. The 
recall period was one month. Using published Swedish unit cost data, the costs 
for home care were estimated in 2012 euros. A semi-logarithmic linear regres-
sion evaluated other factors that may influence the likelihood of getting home 
care. Results: Of 839 respondents, 65.5% had progressive MS, 24.5% had RRMS 
and 10% had no information. Formal care was given to 27% of respondents at 
an average of 238.7 hrs/month at a mean cost of € 2873 per person with MS per 
month. Informal care was received by 49% of respondents at an average of 47.3 
hrs/month at a mean cost of € 389 per person with MS per month. Based on disease 
severity, the mean total home care costs/patient/month were: mild (EDSS 0-3) = 
€ 63, moderate (EDSS 4-6) = € 461 and severe (EDSS > 6.5) = € 8446. Total home care 
costs were three-fold higher in persons with moderate MS and seven-fold higher 
in persons with severe MS versus mild MS. Total home care costs of patients 
cohabiting with another person were nearly 70% higher compared to people liv-
ing alone. The reported average utility was 0.513 (sd 0.307). Utilities across dis-
ease severity: mild MS= 0.709 (sd 0.233), moderate MS= 0.562 (sd 0.232) and severe 
MS= 0.284(sd 0.283). ConClusions: Total home care costs, of which formal care 
costs accounted for a large proportion, increased with increasing disease severity. 
Informal caregiving contributes significantly to MS home care and is an important 
complement to formal home care in Sweden.
PND65
a comParisoN of DemograPHic aND cliNical Variables of DowN 
syNDrome PatieNts iN utaH aND tHe uNiteD states
Jiao T., Liou T.G., Young D., Brixner D.
University of Utah, Salt Lake City, UT, USA
objeCtives: To explore the demographics, comorbidities and medication 
exposure of Down Syndrome (DS) patients in Utah compared to a national 
cohort. Methods: National and local data on adult patients with DS were 
extracted from the General Electric Healthcare National Clinical Data Services 
Warehouse and the University of Utah Healthcare System Enterprise Data, respec-
tively. The ICD-9 code for Down Syndrome (758.0) was used to identify patients, 
alive through 2012, and their associated comorbidities and prescribed medications. 
We used descriptive statistics, t-test, test of proportion and Fisher’s exact test to 
examine relationships between demographics, comorbidities and pharmacothera-
pies and compared results between local and national cohorts. Results: Data was 
extracted on 513 patients in Utah and 11,736 nationally, 98% and 64% of patients 
are adults in cohorts, respectively. Through 2012, adult DS patients in Utah were 
younger (37 vs. 39, p< 0.005), more likely to be female (54.08% vs. 50.47%, p< 0.05) 
and with levodopa in PT patients (72.7%, all p< 0.05). ConClusions: A high and 
comparable level of compliance was observed across PD drugs. Persistence was 
significantly higher than other drugs with rasagiline in treatment-naïve patients 
and with levodopa in previously treated patients.
PND60
Disease-moDifyiNg tHeraPies (Dmt) for multiPle sclerosis (ms): 
aNalysis of its eVolutioN iN sPaiN betweeN 2004 aND 2012
Villoro R.1, Hidalgo A.2
1Instituto Max Weber, Madrid, Spain, 2University of Castilla La Mancha, Toledo, Spain
objeCtives: To analyze determinants of recent evolution of DMT consumption for 
MS in Spain. Methods: Available DMT market data comprised monthly figures 
for the period 2004-2012. Monthly and annual evolution of consumption, treated 
patients and annual cost of treatment were calculated for each DMT. This analy-
sis was replicated for first-line (intramuscular and subcutaneous interferon (IFN) 
β -1a, subcutaneous IFN β -1b, and glatiramer acetate) and second-line therapies 
(natalizumab and fingolimod). Evolution of these variables was analyzed for both 
the whole period 2004-2012 and since 2007 (when second-line therapies become 
available in Spain). Results: DMT expenditure in Spain increased by 147% in 2004-
2012 (from € 115.5M to € 284.9M, 11.95% annually). This evolution can be decomposed 
into: the growth in the figure treated patients (126%; 10.70% annually) and the 
increase in the average annual cost per patient (9%, from € 11,739 to € 12,839; 1.13% 
annually). For 2007-2012 subperiod, DMT spending increased by 73% (11.57% annu-
ally) is attributable to 59% more treated patients (9.73% annually) and an increase 
of 9% (1.68%) in annual cost per patient. Cost per patient in second-line is 70% 
higher (average 2007-2012) than average cost per treated patient (€ 21,074 vs. € 
12,372) and 82% higher than annual cost of first-line therapy (€ 21,074 vs. € 11,549). 
Between 2007 and 2012, second-line therapies accounted 32% of new treatments 
and 48% of incremental cost per patient. By omitting year 2007 from analysis (68 
second-line treatments and € 1.44M associated consumption), second-line therapies 
account for 38% of new treatments and 55% of incremental cost per patient. By 2012 
second-line therapies already represent 50% of new treatments and 67% of DMT 
cost increase. ConClusions: The increase of patients treated with DMT in Spain 
(10.70% annually in 2004-2012), more costly new therapies incorporation and its 
growing consumption are crucial factors in handling hospital pharmacy budgets 
for prevalent diseases such as MS.
PND61
associatioN betweeN NoN-motor symPtoms aND HealtH care 
utilizatioN amoNg PatieNts witH ParkiNsoN’s Disease iN tHe uNiteD 
states
Makaroff L.1, Senior E.1, Moran K.2, Kiri V.3, Thieffry S.1
1UCB Pharma, Brussels, Belgium, 2UCB Pharma, Smyrna, GA, USA, 3FV & JK Consulting Ltd., 
Guildford, UK
objeCtives: To investigate the characteristics and extent of health care utiliza-
tion among patients with Parkinson’s disease (PD) with and without non-motor 
symptoms (NMS). Methods: Data were obtained from a US administrative claims 
database (SDI/IMS). Index date was 1 June 2010, and study duration was 12 months. 
Patients were required to have at least two PD diagnoses before the index date. They 
were subsequently matched 1:1 to control patients (no PD diagnoses) based on 
propensity scores derived from age and pre-index Charlson comorbidity index for 
each gender. Results: In total, 127,630 patients with PD were matched to controls. 
Patients with PD had higher annual mean numbers of primary care (16.4 vs 12.3; 
p ≤ 0.0001) and neurologist visits (6.7 vs 0.4; p ≤ 0.0001) compared with matched 
controls. In the PD group, 48,823 patients (38.3%) had a diagnosis for at least one 
NMS, of whom 15,242 (31.2 %) were also treated for at least one NMS. Most fre-
quently reported NMS were pain (27.2%), mood disturbance (depression, anxiety or 
nervousness; 12.7%) and sleep disorder (7.4%). Patients with pain, mood and sleep 
disorders (n= 1,159), had higher total annual primary care and neurologist visits 
than patients with no NMS (50.7 vs. 17.2). Patients who received treatment for pain, 
mood and sleep disorders (n= 118), had a higher total number of annual primary care 
and neurologist visits (66.6) compared with patients treated only for mood (26.0; 
n= 3,233) only for pain (35.6; n= 9,432), or only for sleep (30.6; n= 676). ConClusions: 
Results of the study demonstrate that treatment of NMS increases health care uti-
lization – patients with PD suffering from NMS had a substantially greater number 
of health care visits than those with no NMS. Results also indicate that there are 
substantial levels of undertreatment of NMS among patients with PD, with less 
than a third being treated.
PND62
Natalizumab treatmeNt is associateD witH reDuceD Neurology 
outPatieNt aPPoiNtmeNts, uNPlaNNeD HosPital aDmissioNs aND 
leNgtH of stay
Beadman A, Hanna J
Biogen Idec Limited, Maidenhead, UK
objeCtives: Global wellbeing of patients is an important outcome in research and 
clinical practice. Multiple Sclerosis (MS) is a degenerative, neurological condition, 
characterised by progressive disability, affecting approximately 110 per 100,000 
people in England and Wales. Natalizumab is a humanised monoclonal antibody, 
licensed for use in highly active relapsing-remitting MS and administered as an 
IV infusion every 28 days. The purpose of this study was to explore the impact of 
natalizumab on both patients and use of health service resource in clinical practice 
in England. Methods: Health Episode Statistics (HES) data were used to perform 
a retrospective cohort study. A structured coding search elucidated a compre-
hensive list of natalizumab users by hospital trust. Analysis of health service 
usage, including outpatient appointments and admissions, was undertaken. 
Comparison of use during the year before and after treatment initiation was con-
ducted. Results: A total of 2,196 patients with at least 1 year of available HES 
data after treatment initiation were identified. In this cohort, natalizumab treat-
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objeCtives: Diagnosis of urinary tract infection (UTI) in young children is difficult. 
Prompt treatment could alleviate short-term symptoms and prevent serious long-
term sequelae, but over-treatment will increase antibiotic resistance. We evaluated 
the cost-effectiveness of a UTI risk score based on signs, symptoms and dipstick test 
findings compared to clinical judgement in guiding urine sampling and antibiotic 
treatment. Methods: We developed a risk score based on urine samples collected 
(by clean catch or nappy pad) in a multicentre diagnostic cohort study (DUTY) of 
7,163 children < 5 years presenting to primary care. The diagnostic value of symp-
toms, signs and dipstick test results were evaluated against a reference standard of 
urine culture results from a research laboratory. We constructed decision-analytical 
models comparing the cost-effectiveness of 3 DUTY risk score thresholds (high 
sensitivity, high specificity or intermediate) versus clinical judgement in younger 
(nappy pad) and older (clean catch) children. We explored the role of the dipstick 
in guiding diagnosis. We considered health service costs and patient utilities dur-
ing the initial diagnosis, acute illness and long-term sequelae. Results: The ‘high 
specificity’ DUTY threshold resulted in fewer urine samples than clinical judgement 
(4.8% vs. 9.2%) with similar sensitivity (58.6% vs. 57.1%) and higher specificity (96.1% 
vs. 91.4%). The difference in short-term net benefits between DUTY thresholds was 
small (range £1088 ‘high sensitivity’ to £1091 ‘high specificity’). In younger children 
(nappy pads) the distinction in cost-effectiveness between the DUTY risk score 
and clinical judgement was not clear-cut. Dipstick tests could potentially expedite 
therapy in higher risk children. ConClusions: Clinicians can reduce prescriptions 
and provide more cost effective care by using the DUTY risk score. Clean catch 
samples should be obtained whenever practical. Low UTI prevalence, imperfect NHS 
laboratory tests and an uncertain link between UTI and long-term sequelae mean 
that conservative sampling strategies may be most appropriate.
Puk3
comParisoNs of tHe cliNical effectiVeNess of treatmeNts for tHe 
symPtoms associateD witH oVeractiVe blaDDer (oab)
Edwards S.J., Karner C., Trevor N., Barton S., Nherera L.
BMJ Group, London, UK
objeCtives: This research was carried out during a review of the manufacturer’s 
submission (MS) to the NICE Single Technology Appraisal programme for the 
selective beta3-adrenoceptor agonist, mirabegron. Antimuscarinics are the main-
stay of treatment for the symptoms of OAB. They may be used at different doses 
and in different formulations (immediate release [IR] or extended release [ER]). 
However, there is limited evidence on their comparative clinical effectiveness 
with each other. This research evaluated the available evidence for mirabegron, 
antimuscarinics, and placebo. Methods: Randomised controlled trials (RCTs) 
for inclusion were identified using the MS for mirabegron. RCTs were assessed 
for comparability based on diagnosis, patient population, treatment regimen, and 
with outcomes reported at 12 weeks. Mixed treatment comparison (MTC) using 
Bayesian Markov Chain Monte Carlo simulation was used to perform a meta-anal-
ysis of a network of RCTs. Summary statistics used were mean difference (MD) for 
continuous outcomes and odds ratio (OR) for dichotomous outcomes. Results: Of 
the 40 RCTs identified in the MS, 22 met the criteria for inclusion in the analysis. 
No statistically significant differences in frequency of micturition were identi-
fied between any of the active treatments. Compared with mirabegron 50mg, 
statistically significant differences in the remaining outcomes assessed, were: 
fewer incontinence episodes, MD (solifenacin 5mg -0.39, 95%CI: -0.72 to -0.06; 
solifenacin 10mg -0.38, 95%CI: -0.69 to -0.07); increased risk of constipation , OR 
(fesoterodine 8mg 2.12, 95%CI: 1.13 to 3.64; solifenacin 5mg 2.11, 95%CI: 1.16 to 
3.59; solifenacin 10mg 4.52, 95%CI: 2.60 to 7.47; trospium 60mg 7.63, 95%CI: 2.12 to 
22.95); increased risk of discontinuation, OR (oxybutynin 15mg IR 2.67, 95%CI: 1.60 
to 4.22). Mirabegron was associated with significantly lower risk of dry mouth than 
all other active treatments. ConClusions: None of the treatments assessed for 
OAB have a consistently superior efficacy with a reduced risk of adverse events.
Puk4
coNtiNuos reNal rePlacemeNt tHeraPy Versus iNtermitteNt 
HemoDialysis: systematic reView oN PatieNt-orieNteD outcomes
Nobre M.R.C.1, Monaco C.F.2
1InCor - HCFMUSP, São Paulo, Brazil, 2Centro Universitário São Camilo, São Paulo, Brazil
objeCtives: Acute renal failure is responsible for about 1% of hospital admissions, 
and occurs in up to 7% of hospitalized patients and up to 20% of patients admitted to 
intensive care units (ICU’s). When it is severe enough to require dialysis, in-hospital 
mortality rate ranges from 50% to 75% and is also increases risk for chronic and 
terminal kidney diseases. Continuous Renal Replacement Therapy (CRRT) in its 
various forms has theoretical advantages over conventionally done Intermittent 
Hemodialysis (IHD) at significantly higher costs, but these advantages attributed to 
CRRT have not yet been consistently proven in terms of clinical outcomes in con-
trolled trials. Methods: We have made a literature search in PubMed to identify 
systematic reviews and randomized controlled trials that studied patient-oriented 
outcomes (mortality and renal recovery). Results: We have found five systematic 
reviews published in 2007 and 2008 and conducted our own metanalysis on six trials 
published from 2001 to 2009 (no clinical outcomes oriented trial has been published 
since them). None of the reviews that directly compared CRRT to IHD have shown 
statistically significant advantages of any of them regarding in-hospital or ICU 
mortality or renal function recovery We have analyzed six randomized no-blinded 
clinical trials that met eligibility criteria of evaluating patient-oriented outcomes 
including 1151 patients. Five of them had high to moderate GRADE scores. None 
have shown absolute risk reduction of in hospital, ICU or at 60 days mortality or 
statistically significant renal recovery rates. Overall mortality relative risk of CRRT 
over IHD was 1,01 (95%CI: 0,92 – 1,11). We found moderate heterogeneity and no 
publication bias. ConClusions: Clinical trials published until October 2012 have 
shown no difference in patient-oriented outcomes between the uses of CRRT and 
IHD techniques in adult patients admitted to intensive care units with acute renal 
failure and requiring renal replacement therapy.
and more likely to be Caucasian (64.61% vs. 41.53%, p< 0.001) than national cohort 
patients. DS patients in Utah suffered significantly more comorbidities: autism 
(6.43% vs. 1.12%, p< 0.001), heart problems (2.53% vs. 0.57%, p< 0.001), blood and 
blood-forming problems (14.81% vs. 10.05%, p< 0.001), epilepsy (7.02% vs. 2.23%, 
p< 0.001) and arthritis (28.46% vs. 10.68%, p< 0.001). Higher proportions of Utah 
patients used ulcer drugs (21.64% vs. 16.83%, p< 0.005), majority PPIs (85.6%); 
antidepressants, (17.93% vs. 11.55%, p< 0.001), majority SSRIs (79.3%); analgesics-
NSAIDs (15.59 % vs. 11.13%, p< 0.005), majority NSAIDs (98.8%); multivitamins 
(16.18% vs. 9.02%, p< 0.001), and fluoroquinolones (10.53% vs. 7.45%, p< 0.01) than 
the national cohort. ConClusions: The Utah DS population differs from the 
comparative U.S. Cohort in demographics, comorbidities and medications. These 
results will be incorporated into the development of a Quality of Life scale to value 
new treatments in Down Syndrome.
PND66
treatmeNt PatterNs for ParkiNsoN’s Disease: real-worlD eViDeNce 
from tHe eu5 (fraNce, germaNy, italy, sPaiN, aND tHe uNiteD kiNgDom)
Sung A.H.1, Kulkarni A.2, Svarvar P.2
1St. John’s University, Queens, NY, USA, 2Merck & Co., Inc., Whitehouse Station, NJ, USA
objeCtives: To assess the distribution of initial Parkinson’s Disease (PD) treat-
ment, along with time to and reasons for changes in therapy. Methods: Adelphi 
Real-World Disease-Specific-Programme (DSP) cross-sectional PD data from 
January 2011 to February 2012 were analyzed. The DSP surveyed 299 physicians 
in the EU5 who completed PD patient reviews (≥ 10 each). Kaplan-Meier estima-
tion was used to evaluate times from initial monotherapy to follow-up therapy 
by treatment. Reasons for adding or switching drug classes were documented 
as efficacy-related, levodopa-related (dyskinesia or on-off fluctuations), due to 
side-effects, and/or other reasons. Results: Of the 3,351 patients included, 60% 
were male; mean age at treatment initiation was 65 years; 55% had mild Hoehn & 
Yahr severity scores (≤ 2.5); and 59% initiated treatment on monotherapy. Overall, 
Dopamine Agonists (DA) were the most common first-line monotherapy (45%; 
mean age 62 years), followed by Levodopa (39%; 71 years), Monoamine-oxidase-B 
Inhibitors (MAOB) (14%; 62 years), and Other (2%; 64 years). The median time 
to change from DA monotherapy was 36 months. Levodopa was the first choice 
add-on (16%) and switch from (5%) DA monotherapy. Reasons for change to 
Levodopa were efficacy-related (92% add-on; 70% switch patients). The median 
time to change from Levodopa monotherapy was 54 months. DA was the first 
choice add-on (13%) and switch from (1.4%) Levodopa monotherapy. Reasons for 
change to DA were efficacy-related (86% add-on; 82% switch patients). The median 
time to change from MAOB monotherapy was 12 months. DA was the first choice 
add-on (32%) and switch from (6%) MAOB monotherapy. Reasons for change to 
DA were efficacy-related (95% add-on; 94% switch patients). ConClusions: This 
EU5 sample represents a levodopa-sparing treatment strategy, favoring initiation 
with DA for younger patients. Initial treatment with Levodopa monotherapy was 
of longer duration than that with DA or MAOB. Physicians predominantly reported 
efficacy-related reasons for treatment changes.
uriNary/kiDNey DisorDers – clinical outcomes studies
Puk1
aNalysis cost effectiVeNess of PHarmacological ProPHylaxis of 
coNtrast-iNDuceD NePHroPatHy
Alonso Herreros J.1, Murcia Murcia C.1, Gonzalez C.uello A2
1HOSPITAL GENERAL REINA SOFIA, MURCIA, Spain, 2UNIVERSIDAD DE MURCIA, MURCIA, 
Spain
objeCtives: Analyze the cost-effectiveness of the prophylaxis (n-acetylcysteine 
1200mg 4 oral-doses+1/6M bicarbonate 500ml IV) of the contrast-induced 
nephropathy (CIN) at risk patients. The CIN is usually reversible, but may affect 
50% of patients with some risk factors (diabetes, age...) and may favor the 
progressive renal damage. Methods: Retrospective observational study. The 
population were patients candidates at prophylaxis protocol CIN in a university 
hospital during 2012 (5142 patients). We calculated a sample size of 115 patients 
for a confidence level of 90%, an error of 7.5% and a frequency of CIN equal 40% 
. CIN was considered as the relative elevation of serum creatinine greater than 
or equal to 25% during the 48 hours after the test. For the economic analysis 
were used acquisition-costs of drugs, and the hemodialysis costs described by 
Lorenzo et al (Nephrology2010,30(4):404-412). We consider, according to litera-
ture that at least 35% of risk patients affected by NIC would require a hemodi-
alysis session. Results: Of the patients who received prophylaxis, 3 had CIN 
and 93 no. Of those who received no prophylaxis 5 had CIN, and 14 no. We did a 
Fisher Test being the difference in favor of the protective effect of the protocol 
statistically significant (p < 0.01). The prophylaxis would have prevented 25.26 
CIN. The prophylaxis costs per patient were € 2.29 . The cost of a hemodialysis 
sessions was € 423. Then € 220.42 has been invested to avoid a minimum of € 
3739.74 on hemodialysis. (16.9 € savings per euro spent on prophylaxis. Each 
avoided NIC had cost € 8.73.) ConClusions: The economic analysis is difficult 
because of the diversity of data about CIN. We chose a cost-minimization model, 
considering minor treatment needs found in the literature. In any case this 
prophylaxis is highly cost-effective and should be considered before introduc-
ing other methods.
Puk2
cost effectiVe use of uriNe samPliNg aND DiPstick testiNg to 
DiagNose uriNary tract iNfectioNs iN Pre-scHool cHilDreN 
PreseNtiNg to Primary care
Busby J.1, Hay A.1, Butler C.2, Lawton M.1, Sterne J.1, Little P.3, Hood K.2, Harman K.1, 
Hollingworth W.1
1University of Bristol, Bristol, UK, 2Cardiff University, Cardiff, UK, 3University of Southampton, 
Southampton, UK
